The Briefing:
- No federal mandate requires clinicians to screen for eating disorders before prescribing GLP-1 weight-loss medications, leaving patients with anorexia legally exposed to drugs that can suppress their remaining biological drive to eat.
- A Yale University secret-shopper study found that 92 percent of the telehealth sites tested would prescribe GLP-1 medications to a simulated patient, with fewer than 56 percent asking whether that patient had any history of an eating disorder.
- A study in JAMA Psychiatry found that more than 40 percent of patients with atypical anorexia nervosa had used a GLP-1 receptor agonist — a figure that exposes both the scale of the problem and the absence of any coordinated clinical safeguard.
The expansion of GLP-1 weight-loss medications into mainstream medicine has been one of the defining pharmaceutical stories of this decade — but a dangerous fault line has opened at its margin. Physicians and eating disorder specialists across the country are now tracking a mounting number of patients with anorexia who have obtained these drugs through telehealth services, often without any meaningful evaluation of their psychiatric history. In a number of cases, the results have been catastrophic.
A CNN investigation published on October 15, 2026 centered the crisis around AJ Jasper, a 40-year-old Chicago man who has lived with anorexia since childhood. Jasper submitted inaccurate information to a telehealth platform to obtain a GLP-1 prescription — and received it without speaking to a physician by phone, video, or in person. His account reflects a pattern that clinicians say they are encountering with increasing frequency.
A System Engineered for Volume, Not Verification
The ease with which Jasper obtained that prescription is not an anomaly — it is, according to research, the industry's standard operating mode. Yale University School of Medicine researchers conducted a secret-shopper study published in the Journal of the American Medical Association in July 2026, submitting a simulated patient profile to 49 telehealth websites that advertise GLP-1 prescriptions. Across those platforms, 92 percent issued a prescription to the simulated patient, and approximately 69 percent went further by shipping the medication — in some cases within minutes of a completed intake form.
The shortfalls in clinical evaluation were equally revealing. Barely more than half of the platforms — approximately 55 percent — asked whether the simulated patient had any eating disorder history. Only about one-third of the sites required any kind of live exchange with a clinician, whether by video or by phone, before writing the prescription. In practice, this creates a pathway through which a patient with a documented history of severe anorexia can obtain a powerful appetite suppressant in the same time it takes to fill out a standard online form.
Multiple patients have acknowledged deliberately falsifying their intake responses — misreporting weight, height, and medical history to secure prescriptions that their own treatment providers would never have authorized.
When Hunger Suppression Becomes a Survival Threat
The clinical logic that makes this combination so dangerous lies in the pharmacology of the drugs themselves. GLP-1 receptor agonists — including semaglutide and tirzepatide, sold under brand names that include Ozempic and Wegovy — reduce appetite by acting on the hormonal pathways that regulate satiety. For most patients, this mechanism is precisely why the medications work. For someone with anorexia, the same pharmacological action can amount to a clinical emergency.
Anorexia is characterized, in part, by already-compromised hunger signaling. Patients in recovery depend, at least in part, on whatever physiological cues still push them toward eating. When a GLP-1 medication further quiets those signals, it does not reduce a patient's anxiety about food — it dismantles one of the last biological forces working in their favor. Medical literature also points to a secondary risk: the rapid, drug-assisted weight loss these medications can produce tends to intensify the distorted body perception that eating disorder treatment is specifically designed to correct. The broader cultural framing surrounding GLP-1 drugs, which frequently celebrates thinness as an achievement, compounds the psychological exposure for patients whose illness is already anchored to that equation.
A Regulatory Landscape Built on Recommendations, Not Rules
At the core of this crisis is an institutional vacuum. No federal standard exists that requires a clinician to screen for eating disorders before issuing a GLP-1 prescription. Major professional bodies in obesity and endocrinology medicine have called for that screening — but the guidance is advisory, and the gap between what is recommended and what actually happens at the point of prescribing is enormous.
A study published in JAMA Psychiatry by researchers at the University of Louisville and RTI International put hard numbers to the overlap between GLP-1 use and eating disorder diagnoses. Among more than 400 adults with eating disorders surveyed for the study, approximately 11 percent of those with anorexia nervosa had used a GLP-1 receptor agonist. Among patients with atypical anorexia nervosa — a form of the disorder in which patients restrict food severely while maintaining a higher body weight, making them far easier to miss in standard screening — the figure exceeded 42 percent.
The Princeton Center for Eating Disorders, a New Jersey treatment facility that recently expanded into partial hospital and intensive outpatient care through a collaboration with Princeton House Behavioral Health, has encountered this dynamic even in cases where a physician conducted a full in-person evaluation. Rebecca Boswell, the center's director, has stated that GLP-1 prescriptions can actively set back eating disorder recovery even when issued through conventional clinical channels — a finding that extends the problem well beyond the boundaries of digital medicine.
Alarm Bells From Around the World
America's Poison Centers, which operates the National Poison Data System, has documented a nearly 1,500 percent rise in calls related to injectable weight-loss drug exposures since 2019. The figure reflects not only the enormous growth in GLP-1 use but also the clinical risks that follow when access expands faster than oversight can.
The danger extends beyond United States borders. ABC News Australia's Health Report program documented a case in August 2026 involving a woman with a confirmed history of anorexia who received a GLP-1 prescription from a telehealth provider after responding to a weight-loss advertisement on Instagram. She had disclosed her eating disorder background during the intake process. She was never screened for it. Australia's National Eating Disorders Collaboration subsequently warned that appetite-suppressing drugs like Ozempic and Wegovy can entrench or accelerate an existing eating disorder, and that meaningful screening is, at present, more the exception than the rule.
Conversion Over Clinical Caution: A Structural Problem
Researchers and clinicians increasingly frame this not as a series of individual failures but as the predictable outcome of how these platforms were designed. Telehealth intake flows are optimized to reduce friction between a potential customer and a shipped prescription. In clinical terms, that design philosophy systematically deprioritizes the diagnostic questions most capable of catching a high-risk patient before the medication leaves the warehouse.
A perspective article published in The New England Journal of Medicine earlier in 2026 raised concern that pharmacological appetite suppression through GLP-1 drugs could conceal or deepen disordered eating patterns in vulnerable patients — particularly in cases where the prescribing clinician has never interacted with them in real time. Regulatory bodies in several countries are now examining tighter oversight of remote pharmaceutical prescribing. Eating disorder specialists, however, argue that the pace of rulemaking has already fallen behind the pace of harm. For patients with anorexia already in the grip of these medications, the distance between what the system currently allows and what clinical medicine demands is not a policy abstraction — for some, it has already proven fatal.
If you or someone you know is struggling with an eating disorder, reach out to the National Alliance for Eating Disorders helpline at 1-866-662-1235.
© {{Year}} Latin Times. All rights reserved. Do not reproduce without permission.